Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
Introduction: Surgery could improve survival of gastroenteropancreatic neuroendocrine tumors (GEP NET). Nevertheless, data on survival prognostic factors come from studies focusing on heterogeneous population including both resected and non-resected patients.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Russolillo N, Ferrero A, Vigano' L, Bertuzzo F, Razzore P,
#766 Aggressive Surgery for Pancreatic Neuroendocrine Tumors
Introduction: The role of surgery for advanced pancreatic neuroendocrine tumor (pNET) requiring extended resections is not well-defined.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Russolillo N, Vigano' L, Ferrero A, Razzore P, Bertuzzo F,
Keywords: pNET, aggressive surgery,
Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Brizzi M, Ferrero A, Ottone A, Bellini E, Bitossi R,
Keywords: paraneoplastic syndrome,
#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Ferrero A, Bellini E, Brizzi M, Pia A, Ottone A,
Keywords: malignant insulinoma, everolimus, resistant hypoglycemia,
Introduction: Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Rossi R, Massironi S, Ferrero S, Spampatti M, Conte D,
Keywords: Gastrointestinal Stromal Tumors (GISTs), Multiple Endocrine Neoplasia 1 (MEN-1) syndrome, gastrinoma,
Our website automatically sets cookies, which are technically necessary for the operation of the website. By clicking "OK", Google Analytics and the associated cookies are also activated for the purpose of website analysis and optimization. Detailed Information and the possibility to revoke your consent at any time, you can find in our privacy policy.
These cookies are so-called "session cookies." They are automatically deleted after your visit.
Protects you from Cross-Site-Request-Forgery attacks.
Saves the current PHP session.
For webinar purposes, ENETS uses VIMEO as an embedded iframe on MY ENETS. VIMEO implements its own tracking system, which is beyond the of ENETS responsibility. By watching ENETS videos on the ENETS website, you also agree to the conditions of VIMEO: https://vimeo.com/privacy
This website uses Google Analytics, a web analytics service. It is operated by Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, USA. Google Analytics cookies are stored based on your consent Art. 6 (1) (a) DSGVO/GDPR, which we confirm via the consent banner.
For more information about how Google Analytics handles user data, see Google's privacy policy: https://support.google.com/analytics/answer/6004245?hl=en.